Consideration of use of phenothiazines in particular trifluorperazine for epidermal growth factor receptor associated cancers

Medical Hypotheses

Volumn 69, Issue 5, 2007, Pages 1074-1075

  Kast, Richard E ^a   Altschuler, Eric Lewin ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b University of Medicine and Dentistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHENOTHIAZINE; TRIFLUOPERAZINE;

ARTICLE; BREAST CANCER; CANCER; COLON CANCER; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SCHIZOPHRENIA;

HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHENOTHIAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRIFLUOPERAZINE;

EID: 34548738145     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.08.048     Document Type: Article

References (6)

1. Frieze D.A., and McCune J.S. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 40 (2006) 241-250
2. Halatsch M.E., et al. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32 (2006) 74-89
3. Goyns M.H., and Hopkins C.R. Inhibition of epidermal growth factor-induced mitogenesis in bovine granulose cells by trifluoperazine. Biochem Biophys Res Commun 102 (1981) 1107-1114
4. DiPaola M., Keith C.H., Feldman D., Tycko B., and Maxfield F.R. Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides. J Cell Physiol 118 (1984) 193-202
5. Ross A.H., Damsky C., Phillips P.D., Hwang F., and Vance P. Inhibition of epidermal growth factor-induced phosphorylation by trifluoperazine. J Cell Physiol 124 (1985) 499-506
6. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30